Bladder cancer Analysis of Subtype by gene Expression, NanoString-derived BASE47 platform, RNAseq transcriptomic data to differentiate between basal-like and luminal-like subtypes, muscle-invasive urothelial tumors.
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer. This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Matthew…
bladder cancer, Circulating Tumor DNA (ctDNA), Residual Disease Detection, imvigor010 study, immunotherapy, adjuvant therapy, urine tumor DNA markers, treatment of invasive bladder cancer.
Tanya Stoyanova discusses research on Trop2’s role in prostate cancer, published in Nature Scientific Reports. Collaborating with Drs. Michael Liss and Jim Brooks, the study…
bladder cancer, metastatic urothelial carcinoma, EV-302 trial, KEYNOTE-A39 study, enfortumab vedotin, pembrolizumab, enfortumab vedotin plus pembrolizumab, CheckMate 901 study, nivolumab plus gemcitabine/cisplatin, nivolumab, gemcitabine, antibody-drug…
Guru Sonpavde and Matt Galsky delve into the CheckMate 901 study and its implications for advanced bladder cancer treatment. Dr. Sonpavde outlines the study’s design,…
Zach Klaassen and Rob Svatek explore the potential of cretostimogene, a novel medication for non-muscle invasive bladder cancer. Dr. Svatek describes cretostimogene as an oncolytic…
Andrea Miyahira hosts a discussion with Veda Giri, Ayesha Shafi, and Claire Fletcher, members of the PCF Women in Science Forum Organizing Committee. The forum…
Andrea Miyahira talks with Louise Emmett who shares her unconventional journey into nuclear medicine, sparked by a contrarian spirit and a suggestion against pursuing the…
Zach Klaassen engages with Colin Pritchard in a detailed discussion about genomic testing in prostate cancer. They emphasize the importance of genomic testing, particularly in…
Alicia Morgans interviews Neeraj Agarwal about the CONTACT-02 trial, a phase III study that explores the combination of cabozantinib and atezolizumab in patients with metastatic…
